Table 1 Number of participants enrolled and finishing follow-up and characteristics at baseline
Benguela | Zaire | Lunda Sul | ||||
|---|---|---|---|---|---|---|
DPb | ASAQa | ALa | ASAQa | ALa | DPb | |
Enrollment and follow-up | ||||||
Enrolled, n | 100 | 105 | 100 | 98 | 105 | 100 |
Lost to follow up, n (%) | 5 (5) | 2 (2) | 3 (3) | 5 (5) | 5 (5) | 7 (7) |
Excluded, n (%) | 10 (10) | 12 (11) | 3 (3) | 3 (3) | 9 (9) | 4 (4) |
Reached study endpoint, n (%) | 85 (85) | 91 (87) | 94 (94) | 90 (92) | 91 (87) | 89 (89) |
Participant characteristics at baseline | ||||||
Median age, years (range) | 7.1 (2–12) | 6.3 (2–12) | 3 (0.5–5) | 2.7 (0.8–5) | 3.3 (0.6–5) | 3 (0.5–5) |
Median weight, kg (range) | 20 (9–48) | 19 (10–52) | 12 (7–20) | 12 (7–19) | 12 (6–20) | 12 (6–19) |
Percent female (%) | 53 | 53 | 46 | 55 | 54 | 47 |
Median day 0 parasitaemia, parasites/µL (range) | 25,940 (1218–95,585) | 31,399 (1242–97,167) | 47,607 (2175–182,138) | 31,215 (2848–184,243) | 22,340 (2162–122,064) | 19,812 (3316–184,465) |
Median day 0 haemoglobin, g/dL (range) | 10.5 (8.1–13.9) | 10.7 (8.1–15.1) | 10.1 (8.1–13.0) | 9.7 (8.1–13.0) | 9.5 (8.1–12.8) | 9.3 (8.1–14.9) |